Jeffrey F. Eisenberg - 11 Dec 2023 Form 4 Insider Report for Xenetic Biosciences, Inc. (XBIO)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: XBIO
Reported as of: 11 Dec 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Dec 2023, 17:30:08 UTC
Prior SEC filing: 28 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey F. Eisenberg

Filing notes and source

Key filing fact

Jeffrey F. Eisenberg filed Form 4 for Xenetic Biosciences, Inc. (XBIO) on 13 Dec 2023.

Key facts

This page summarizes Jeffrey F. Eisenberg's Form 4 filing for Xenetic Biosciences, Inc. (XBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Dec 2023, 17:30.

Change

Previous filing in this sequence was filed on 28 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XBIO transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 11 Dec 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $3.88
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026.